NOVARTIS PHARMACEUTICALS CORPORATION - PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML)

PIID: 36C24226N0216Solicitation ID: 36C24226Q0080

Signed Date: Feb 6, 2026Effective Date: Nov 1, 2025End Date: Closes in 141 days

Award $

$813K

Vendor

NOVARTIS PHARMACEUTICALS CORPORATION

NAICS

325412

Signed Date

Feb 6, 2026

Key Details

Dollars Obligated

$813,476.16

Base & All Options

$514,413.9

Awarding Agency

Department of Veterans Affairs

Awarding Sub-Agency

Department of Veterans Affairs

NAICS Code

325412 - PHARMACEUTICAL PREPARATION MANUFACTURING

Product Service Code

6505 - DRUGS AND BIOLOGICALS

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

EAST HANOVER, NJ, 079361080, CD-NJ-11

Description

PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML)

Context & Analysis

On Feb 6, 2026, Department of Veterans Affairs obligated $813,476.16 to NOVARTIS PHARMACEUTICALS CORPORATION for pluvicto (lutetium lu 177 vipivotide tetra 27mci/ml). The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in EAST HANOVER, NJ. The contract is scheduled through Oct 31, 2026 — approximately 5 months remaining.